AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 2. (Cancelled)

3. (Previously Presented) A compound of claim 18 wherein:
R^2 is $(C_1\text{-}C_4)$alkyl substituted with $-NR^4R^5$ or $-C(=O)NR^4R^5$;
R^4 is $(C_1\text{-}C_6)$alkyl substituted with $-S(=O)CH_3$, $-NHC(=O)CH_3$ or $-C(=O)NR^7R^8$;
R^5 is H or methyl; and
R^7 and R^8 are the same or different and are H or methyl.

4. (Cancelled)

5. (Previously Amended) A compound of claim 18 wherein:
R^2 is $(C_1\text{-}C_6)$alkyl substituted with $-S(=O)R^3$;
R^3 is $(C_1\text{-}C_6)$alkyl optionally substituted with one to three groups selected from $-S(=O)R^6$, $-SO_2R^6$, $-NR^7R^8$, $-OR^7$, $-NR^7C(=O)R^7$, $-NR^7SO_2R^6$;
$-C(=O)NR^7R^8$; and $-O\text{-}C(=O)NR^7R^8$; wherein
R^6 is $(C_1\text{-}C_6)$alkyl and R^7, R^7 and R^8 are the same or different and are H or $(C_1\text{-}C_6)$alkyl.

6. (Previously Presented) A compound of claim 18 wherein R^2 is $(C_1\text{-}C_6)$alkyl substituted with $-S(=O)R^3$; and R^3 is $(C_1\text{-}C_6)$alkyl.

7. (Cancelled)

8. (Previously Presented) A compound of claim 18 wherein:
R^2 is $Q^1\text{-}Q^2\text{-}Q^3\text{-}Q^4$;
Q^1 is a single bond;
Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;
Q^3 is $-CH_2-$;

Q^4 is a 5-membered aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q^2 bound to Q^1 is a carbon atom; and

the atom of Q^4 bound to Q^3 is a carbon atom.

9. (Previously Presented) A compound of claim 18 wherein R^1 is –Cl or –F.

10. (Previously Presented) A compound of claim 18 wherein m is 2.

11. (Previously Presented) A compound according to claim 18 and selected from the group consisting of:

5'-(2-[(2-amino-2-oxoethyl)amino]ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-chloro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

5'-(2-{[2-(acetylamino)ethyl]amino}ethoxy)-8'-chloro-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-[3-(methylsulfinyl)propoxy]-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one;

8'-fluoro-5'-([methylsulfinyl]methoxy)-1'H-spiro[cyclohexane-1,4'-quinazolin]-2'(3'H)-one; and

8'-fluoro-5'-(2-{[1-(1H-pyrazol-3-ylmethyl)azetidin-3-yl]oxy})-1'H-sprio[cylclohexane-1,4'-quinazolin]-2'(3'H)-one.

12. (Cancelled)

13. (Previously Presented) A method of treating acquired immune deficiency syndrome (AIDS) in a mammal, comprising administering to said mammal in need thereof a compound of claim 18.

14. – 16. (Cancelled)

17. (Previously Presented) A pharmaceutical composition comprising a compound of claim 18 together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system.

18. (Currently Amended) A compound of formula (I):



wherein

m is 1, 2 or 3;

R^1 is selected from CH_3, Cl, Br and F;

R^2 is selected from

(a) Q^1-Q^2-Q^3-Q^4 wherein:

Q^1 is a single bond or a linear or branched ~~(C_3-C_4)~~ (C_1-C_6) alkylene group;

Q^2 is a saturated 4- to 6-membered heterocycle comprising a nitrogen atom;

Q^3 is a linear (C_1-C_4)alkylene group;

Q^4 is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with methyl;

the atom of Q^2 bound to Q^1 is a carbon atom; and

the atom of Q^4 bound to Q^3 is a carbon atom;

(b) (C_1-C_6)alkyl, said alkyl group being substituted with a group selected from OR^4, $COOR^4$, NR^4R^5, $NRC(=O)R^4$, $C(=O)NR^4R^5$ and $SO_2NR^4R^5$, wherein;

R is H or (C_1-C_6)alkyl;

R^4 is (C_1-C_6)alkyl substituted with 1 to 3 groups selected from $S(=O)R^6$, SO_2R^6, $NRC(=O)R^7$, $NRSO_2R^6$, $C(=O)NR^7R^8$, O-$C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is (C_1-C_6)alkyl and R, R^7 and R^8 are the same or different and are selected from H and (C_1-C_6) alkyl; and

R^5 is selected from R^4, H and $(C_1\text{-}C_6)$alkyl;

(c) $(C_1\text{-}C_6)$alkyl, said alkyl group being:
substituted with 1 to 3 groups selected from $OC(=O)R^{4a}$, SR^{4a}, $S(=O)R^3$, NR^aCOOR^{4a}, $NR^a\text{-}C(=O)\text{-}NR^{4a}R^{5a}$, $NR^a\text{-}SO_2\text{-}NR^{4a}R^{5a}$, and $NR^a\text{-}SO_2\text{-}R^3$, and
optionally substituted with OH or OCH_3;
wherein
R^a is selected from H and CH_3;
R^3 is $(C_1\text{-}C_6)$alkyl, unsubstituted or substituted with 1 to 3 groups, selected from F, CN, $S(=O)R^6$, SO_3H, SO_2R^6, $C(=O)\text{-}NH\text{-}SO_2\text{-}CH_3$, OR^7, SR^7, $COOR^7$, $C(=O)R^7$, $O\text{-}C(=O)NR^7R^8$, NR^7R^8, $NR^7C(=O)R^7$, $NR^7SO_2R^6$, $C(=O)NR^7R^8$ and $SO_2NR^7R^8$, wherein R^6 is $(C_1\text{-}C_6)$alkyl and R^7, R^7 and R^8 are the same or different and are selected from H and $(C_1\text{-}C_6)$alkyl;
R^{4a} and R^{5a} are the same or different and are selected from H and R^3;
their racemic forms, their isomers or their pharmaceutically acceptable salts.